Introduction
I n the pre-highly active antiretroviral therapy era (HAART, or ART; please note that HAART serves as a historical term for this article. We will refer to such HIV treatment regimens as ''antiretroviral therapy'' or ART), opportunistic infections of the eye were frequent and often severe. 1 However, the epidemiology of eye involvement in HIV has changed as a result of our ability to control HIV disease with newer ART regimens. [2] [3] [4] [5] [6] [7] The incidence and overall severity of opportunistic infectious diseases of the eye have decreased, along with other sequelae of immunosuppression.
The stark contrast in HIV eye diseases before and after the introduction of ART has been described in the literature. 8 However, epidemiologic differences in HIV eye disease that have occurred during the ART era have not been as well established. Recent studies still estimate that approximately 40% of patients with AIDS and no evidence of infectious retinitis still demonstrate significant visual impairment. 9 Such ongoing disease may be indirectly due to a persistent systemic inflammatory state (the hypothesized etiology of HIV retinopathy) or due to the aforementioned increase in incidence of additional non-AIDS related comorbidities in today's HIV patients (diabetes or hypertension, for instance).
The aim of this study is to review retrospectively a population of HIV-positive hospitalized patients with eye disease over this time period of ART evolution. We then compare the epidemiology of eye disease in patients seen in the early era of ART with the more recent era of ART.
Methods

Patient population
HIV-infected adults with active ocular disease admitted as inpatients for any reason to the Wills Eye Institute and Thomas Jefferson University Hospitals between December 30, 1995 and October 31, 2010 were identified through a search of applied International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) codes including HIV (042, V08) and any ocular diagnosis (360-379).
An initial 422 admissions were identified. Of these, 9 charts were unavailable, 129 admissions were noted to have no active ocular diagnosis, 59 were noted to be duplicate patient admissions without a new ocular diagnosis, and 3 admissions did not have confirmed HIV by history or laboratory testing. These cases were excluded, leaving 222 admissions amongst 188 patients.
A retrospective chart review was conducted. Data for the study were collected from included charts. Demographic patient information collected included age, gender, race, substance abuse history, CD4 + T cells/lL, HIV viral load, current antiretroviral therapy, and select co-morbidities (Table 1) .
Outcome
Active ocular diagnoses were recorded for each admission. Visual acuity was documented when available (160 of 188 patients had a full ophthalmologic exam with full visual acuity). All patients in the study with documented visual acuity received a full ophthalmologic exam. For the 22 patients without documented visual acuity, documentation of further ophthalmologic examination was not recorded.
Patients and their active ocular diagnoses were divided into comparison groups based on date of presentation. An ''Early ART'' arm of the study consisted of presentations from December 30, 1995 through June 30, 2003. A ''Late ART'' arm of the study consisted of presentations from July 1, 2003 through October 31, 2010.
For this study, 2003 was chosen as a separation time point between study groups. Prior to 2003, protease inhibitor (PI) regimens still proved cumbersome and triple-nucleotide reverse transcriptase inhibitor (NRTI) regimens still remained in use. In 2003 and beyond, newer, better-tolerated medications such as atazanavir, fosamprenavir, and fixed-dose combination pills such as tenofovir/emtricitabine and tenofovir/ emtricitabine/efavirenz became available. Therefore, 2003 seemed a reasonable time to demarcate an ''early'' time frame capturing patients on first-generation PIs and NRTIs versus a ''late'' time frame capturing patients on modern PIs, fixeddose combination pills, and NNRTIs.
Statistics
p Values were obtained with the unpaired t-test, chi-square test, or Fisher's exact test and adjusted by false discovery rate methods, when indicated.
Results
From the 222 admissions, 252 active ocular diagnoses were identified (please refer to Table 4 for a complete breakdown by anatomic location). Sixty patients were included in the early ART arm of the study, and 128 patients were included in the late ART arm ( Table 1) .
Immunologic and virologic comparison of the two patient groups illustrated a significantly higher median CD4 + count in the late ART patients compared with the early ART patients (108 vs. 40 cells/lL). The late ART group also had significantly fewer patients with uncontrolled viral load (defined as > 400 copies/mL) compared with the early ART group (65% vs. 88.5% of patients). In addition, late ART patients were less likely to have had an opportunistic infection in the past (36.4% of late ART patients had a history vs. 72.2% of early ART patients). The late ART group of patients, however, tended to have more co-morbidities compared to the early ART patients. Most significantly, patients in the late ART group had a 15.9% prevalence of malignancy versus only a 1.8% incidence in the early ART group. Late ART patients also had a significantly higher prevalence of diabetes mellitus compared to their early ART counterparts (16.7% vs. 7% prevalence). While not statistically significant, late ART patients also tended to have a higher prevalence of cardiovascular disease and chronic viral hepatitis ( Table 1) .
Among the early ART patients, 77 ocular diseases were diagnosed, while 175 ocular diseases were diagnosed in the late ART group. Ocular disease in both groups combined was predominately noninfectious (57%). Ocular diagnoses were compared in early and late ART groupings. Early ART diagnoses had significantly more infectious eye disease occurrence compared to the late ART group (54.6% of cases vs. 37.7%) ( Table 2) .
The most frequent ocular diagnoses (from Table 4 ) found in the early and late ART groups were compared with p values calculated for the differences in prevalence ( Table 3 ) (note that p values were not calculated for differences in all diagnoses from Table 4 , just for the most frequent that appear in Table 3 ). Most notably, 28.6% of ocular disease in the early ART group was CMV retinitis (Fig. 1 ) compared to only 7.4% in the late ART group. This diagnosis represented the highest burden of ocular disease in early ART patients by a large margin. In contrast, the incidence of ocular disease diagnoses in the late ART group was more evenly distributed amongst a wide range of categories.
The late ART group did have a significantly higher rate of severe vision impairment, however, when visual acuity was documented. Forty-eight patients in the early ART group and 112 patients in the late ART group had visual acuity documented. While the percentage of patients with ''mild'' visual impairment ( < 20/40 but ‡ 20/200) was roughly equal (22.9% of early ART patients vs. 19 .6% of late ART patients, p value of 0.64), the percentage of patients with ''severe'' visual impairment ( < 20/200) was significantly more for the late ART group (37.5% of early ART patients versus 58% of late ART patients, p value of 0.02).
Discussion
Ocular disease is associated with human immunodeficiency virus (HIV) infection. [10] [11] [12] Ocular manifestations of HIV infection have been well described in the pre-ART era of HIV infection when patients frequently developed severe immunodeficiency followed by the development of opportunistic infections. Direct therapy (ganciclovir for cytomegalovirus, or CMV retinitis, for instance) for such opportunistic infections provided limited benefit in patients suffering from a progressively failing immune system. 13 With the approval of zidovudine as the first antiretroviral therapy for HIV in 1987, the face of HIV disease began to change. The most dramatic change came in the mid-1990s with the introduction of ART, which made preservation of T-cell immunity and suppression of HIV possible. Early ART regimens, however, were inconvenient and cumbersome for patients due to high pill burdens, food restrictions, and intolerable side effects. [2] [3] [4] [5] [6] [7] Drug compliance, and therefore control of HIV disease, remained a challenge. With time, however, drugs with better tolerability, potency, and efficacy have been developed. Such developments have even made it possible to include a complete ART regimen co-formulated into one pill taken once daily. As a result, compliance and control of HIV are now much more realistic goals.
Eye disease caused by infectious agents such as Toxoplasma gondii (Fig. 5 ), varicella-zoster virus (VZV) (Fig. 3) , and, most notably, CMV (Fig. 1) , were disproportionately represented in HIV patients before HAART became widely available. One autopsy study from the pre-ART era found a 32% incidence of postmortem HIV-infected patients with evidence of CMV retinitis, 14 and that the incidence of clinically apparent CMV retinitis in individuals with severe T-cell impairment (CD4 + < 100 cells/lL) may be as high as 25%. 15 Frequently, HIVinfected patients with CMV retinitis progressed to retinal detachment and severe visual impairment months after the onset of visual disturbance.
As control of HIV has improved, the incidence of opportunistic infections decreased. [2] [3] [4] [5] [6] [7] 11 One epidemiologic study from 1996 to 2004 found a 92% decrease in AIDS-related mortality in HIV patients while ART utilization increased from 43% to 82% 
EYE DISEASES
over this period 16 (this includes eye diseases such as CMV: several epidemiologic studies of the late 1990's estimate a 50-80% decrease in the incidence of CMV retinitis alone since the introduction of ART [17] [18] [19] . Consequently, the incidence of non-AIDSrelated mortality significantly increased over this time period. [2] [3] [4] [5] [6] [7] Today's HIV practitioners often face their most significant challenges from noninfectious co-morbidities such as coronary artery disease, osteoporosis, chronic kidney disease, hyperlipidemia, liver disease, and non-AIDS defining malignancies. In our study, noninfectious eye disease was more common overall than infectious disease. In the early ART group, however, infections represented the majority of eye diseases that were seen. The significant decrease in opportunistic in-fections in the late ART group supports the conclusion that ART may have been a less effective intervention in the early ART group. The median time since HIV diagnosis in the early and late groups was 6 and 7.5 years, respectively. Despite an average year and a half added exposure to HIV infection, late ART patients were far less likely to have had an opportunistic infection. One could subsequently conclude that improved efficacy of ART in the late group directly impacted the incidence of infectious eye diseases.
A bias towards an increased number of opportunistic infections in the early ART group may very well exist in this study, however. Many patients in the early ART group may have acquired their opportunistic infections prior to the 
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availability of any effective antiretrovirals. They may have subsequently survived long enough to be included in the early ART group. Many such patients may not have survived long enough, however, to be included in the late ART group. A better understanding of HIV treatment and prevention of opportunistic infections may have prevented acquisition of such infections for late ART patients and may partially ac-count for the decreased prevalence of opportunistic infections in the late ART group. An additional caveat exists in that HIV eye diseases that were frequently managed in the inpatient setting in the 1990s can now be managed in the outpatient setting. For example, a regimen of oral valganciclovir in combination with ART could now potentially be used to treat CMV retinitis in the outpatient setting. However, such a diagnosis would almost universally prompt an inpatient admission in the time frame captured by the early ART group. As this study only examined eye diseases in inpatients, fewer patients with true infectious eye disease may have been captured in the late ART group, since these patients may have been able to avoid hospital admission altogether.
In addition, lack of initial insurance reimbursement for PIs made their availability to patients impractical in many cases until the late 1990s. Therefore, despite the existence of PIs throughout the early ART time period, these effective HIV medications may not have been widely employed over that same time frame, and opportunistic infections may therefore have developed with greater frequency in this group.
The majority of patients with ocular disease, whether infectious or not, experienced diminished visual acuity (when documented). Patients in the late ART group were significantly more likely to have documented visual acuity ( < 20/ 200) as compared to early ART patients. Our data concur with other larger studies 10 that also illustrate that visual impairment remains a significant problem in the HIV population, despite improved control of HIV. Emerging noninfectious eye diseases in HIV patients are likely to continue to have an impact on vision, despite improved control of HIV. HIV practitioners, who may be unaware of the potential effects of noninfectious causes of visual impairment, may inadvertently leave evolving eye disease unaddressed.
In conclusion, ART has significantly changed the epidemiologic landscape of HIV disease. The incidence of lifethreatening opportunistic infections has significantly decreased in the setting of newer, more efficacious, and better-tolerated antiretroviral drugs for those individuals who are diagnosed, who are retained in care, and who remain on ART with a suppressed viral load. Noninfectious co-morbidities are often of more pressing concern to the health of HIV patients taking modern ART regimens.
This generalization appears to be true with regard to eye disease in the HIV patient as well. Vision-threatening opportunistic infections such as CMV retinitis were commonly seen prior to the development of antiretroviral medications. Such infections still represented a significant disease burden amongst patients taking early-generation ART regimens; however, it appears that newer iterations of ART are causing a decrease in the incidence of such opportunistic eye infections. Noninfectious eye diseases now appear to be a more significant threat to vision in the late ART HIV patient.
These study data have several limitations. Most notably, this study is a small, cross-sectional examination with an inherent selection bias, since only hospitalized patients were included. These data may not reflect a true representation of eye disease in the general HIV population. Furthermore, patients without subjective eye complaints may have never received an ocular diagnosis, and therefore subclinical eye disease may not have been discovered. Also of note, some demographic information for the patients in this study was unavailable and therefore incomplete.
With these limitations in mind, we conclude that our data provide evidence of a shift in the epidemiology of HIV eye disease. Noninfectious pathology seems to be a more significant cause of visual loss in the late ART era. This observation is consistent with the shifting epidemiology of HIV morbidity and mortality in general and underscores the continued need for routine eye care as a component of the comprehensive management of HIV infected patients.
